JBIOJade Biosciences, Inc.

1. Sep 30, 2026On September 30, 2026, Jade Biosciences, Inc. (“Jade”) announced preclinical data characterizing JADE301, its anti-interferon beta (“IFN-ß”) monoclonal antibody in development for dermatomyositis (“DM”), a rare, chronic and debilitating autoimmune disease characterized by painful inflammatory skin disease and …Other event · Form 8-K
2. Aug 10, 2026Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update.Earnings release · press release
3. Jul 1, 2026On June 29, 2026, Jade Biosciences, Inc. (the “Company”) entered into a License Agreement (the “JADE301 License Agreement”) with Paragon Therapeutics, Inc. (“Paragon”), pursuant to which Paragon granted the Company a royalty-bearing, worldwide, exclusive and sublicensable license to use, make, sell, import, export and …Material agreement entered · Form 8-K
4. Jun 26, 2026On June 25, 2026, the Board of Directors (the “Board”) of Jade Biosciences, Inc. (the “Company”) appointed Mark Eisner, M.D., M.P.H., to serve as a Class I director of the Company, to hold office until the Company’s 2028 annual meeting of stockholders and until his successor is duly elected and qualified or until his …Director or officer change · Form 8-K
5. Jun 4, 2026On June 3, 2026, Jade Biosciences, Inc. (“Jade” or the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC and UBS Securities LLC, as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the …Other event · Form 8-K
6. Jun 1, 2026On June 1, 2026, the Company announced interim results from its Phase 1 healthy volunteer trial evaluating JADE101in development for the treatment of IgAN. JADE101 is designed with ultra-high binding affinity to selectively block APRIL, a key driver of pathogenic IgA production in IgAN, a chronic autoimmune disease …Regulation FD disclosure · Form 8-K
7. May 7, 2026Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update.Earnings release · press release
8. Apr 22, 2026On April 18, 2026, the Board of Directors of Jade Biosciences, Inc. (the “Company”) appointed Andrew King, BVMS, Ph.D. as the Company’s President, Research & Development, effective as of April 18, 2026.Director or officer change · Form 8-K
9. Apr 2, 2026On March 31, 2026, the Board of Directors (the “Board”) of Jade Biosciences, Inc. (the “Company”) approved the Jade Biosciences, Inc. 2026 Employment Inducement Stock Incentive Plan (the “2026 Inducement Plan”)Director or officer change · Form 8-K
10. Mar 6, 2026Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update.Earnings release · press release
11. Jan 5, 2026Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference.Earnings release · press release

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.